Covering all aspects of the pharma industry and across all therapeutic areas, Kevin has interviewed pretty much all the leading figures in the sector. A regular attendee at financial and medical conferences (and moderating at some), he has also appeared on BBC television and radio, ITV and Channel 4 to discuss the industry. Fluent in Spanish, he previously worked as a journalist on rock/pop music publications, was chief sub editor at Catholic newspaper The Universe and contributed articles to the likes of The Independent and the Manchester Evening News on football.
Latest from Kevin Grogan
The Carlyle-backed venture capital group is said to be working on a new fund to help finance up to eight late-stage clinical studies through potential partnerships with big pharma for a share of royalties. The move would be in keeping with its recent investment activities.
While most drug development in the multiple sclerosis space has focused just on relapse prevention, Immunic’s dual-acting therapy vidofludimus calcium also offers a novel approach for neurodegeneration, its CEO Daniel Vitt tells Scrip.
The Norwegian biotech is losing a big pharma partner and up to half of its staff, but remains confident about the prospects for its personalized cancer vaccine programs.
Deal Snapshot: The essential tremor space has not seen innovation in treatment for decades. Acadia believes Saniona's GABAA-α3 positive allosteric modulator could be the answer.
The Swiss major’s chief medical officer tells Scrip about how “an R&D/commercial continuum” is helping to speed up innovation across the group.
CEO Vas Narasimhan has highlighted the strong momentum from six new products plus the old favorites Entresto and Cosentyx, saying that there are over 30 high-value medicines in the pipeline that will drive continued mid-single digit sales growth beyond 2029.